Zai Lab Limited American Depositary Shares (ZLAB)
Stock · NASDAQ · Health Care
$23.19as of 10/16/2026
Price chart
Active signals
ZLAB Signal Track Record
How signals performed across all stocks →What ZLAB's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -1.3% | 49% | August 7, 2026 |
| Bollinger Band Breakdown | 23 | +1.7% | 57% | September 10, 2026 |
| Bollinger Band Breakout | 23 | -6.8% | 30% | August 7, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -10.7% | 17% | July 16, 2026 |
| Any 20-session window (baseline) | -1.6% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ZLAB
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myastheni…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,784
- Website
- www.zailaboratory.com/
Fundamentals
- 1-day range
- $23.37$24.29
- Market cap
- $2.35B
- P/E (trailing)
- —
- P/E (forward)
- -11.08
- EPS (trailing)
- $-0.17
- Dividend yield
- —
- Beta
- 0.31
- Avg. volume
- 928.3K
How Zai Lab Limited American Depositary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Zai Lab Limited American Depositary Shares Competitors
Chosen by industry and closest market cap.
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
- VRDNViridian Therapeutics Inc. Common Stock$19.03▼ 2.71%Market cap $2.32BP/E —$13.18$34.29
- VERAVera Therapeutics Inc. Class A Common Stock$27.88▼ 2.42%Market cap $2.30BP/E —$23.05$56.05
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
- KLRAKailera Therapeutics Inc. Common Stock$11.25▼ 3.93%Market cap $2.44BP/E —$9.76$28.23
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $19.03 | ▼ 2.71% | $13.18$34.29 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $27.88 | ▼ 2.42% | $23.05$56.05 |
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
| KLRA Kailera Therapeutics Inc. Common Stock | $2.44B | — | $11.25 | ▼ 3.93% | $9.76$28.23 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- William Lis · August 12, 2026 · Sale8.5K @ $25
- Yajing Chen · August 11, 2026 · Sale619 @ $25
- Du Ying · July 2, 2026 · Grant80.4K
- Du Ying · July 2, 2026 · Option Exercise11.0K
- Du Ying · July 2, 2026 · Tax Withholding4.3K @ $19.12
- Richard Gaynor · July 1, 2026 · Buy1.7K @ $19.05
- Du Ying · July 1, 2026 · Option Exercise18.0K
- Du Ying · July 1, 2026 · Tax Withholding7.1K @ $19.15
- Du Ying · June 30, 2026 · Sale7.0K @ $18.53
- Du Ying · June 29, 2026 · Option Exercise18.0K
- William Lis · June 22, 2026 · Sale7.0K @ $18.09
- Richard Gaynor · June 17, 2026 · Grant22.4K
- Nisa Leung · June 17, 2026 · Grant22.4K
- Michel Vounatsos · June 17, 2026 · Grant22.4K
- Scott W. Morrison · June 17, 2026 · Grant22.4K
Institutional Ownership
March 31, 2026
- Total shares held
- 28.56M
- Total value held
- $521.49M
- Institutional holders
- 97
- Unknown6.57M
- Unknown5.71M
- Unknown1.90M
- Unknown1.72M
- Unknown1.66M
- Unknown1.43M
- Unknown1.26M
- Unknown865.1K
- Unknown814.7K
- Unknown510.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Zai Lab Releases Q2 2026 Earnings and Call Transcript
Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.
Zai Lab Releases Q2 2026 Earnings and Call Transcript. Zai Lab has published its second-quarter 2026 financial results along with the full earnings call transcript. This update provides investors with the latest details on the company's performance and strategic outlook. The stock is currently trading within its 52-week range, with analysts maintaining a wide target price spread.